

World Journal of *Gastroenterology*

World J Gastroenterol 2022 September 7; 28(33): 4744-4928



REVIEW

- 4744 Regulation of transforming growth factor- β signaling as a therapeutic approach to treating colorectal cancer

Maslankova J, Vecurkovska I, Rabajdova M, Katuchova J, Kicka M, Gayova M, Katuch V

MINIREVIEWS

- 4762 Immunological mechanisms of fecal microbiota transplantation in recurrent *Clostridioides difficile* infection

Soveral LF, Korczagin GG, Schmidt PS, Nunes IS, Fernandes C, Zárate-Bladés CR

- 4773 Albumin administration in patients with cirrhosis: Current role and novel perspectives

de Mattos ÁZ, Simonetto DA, Terra C, Farias AQ, Bittencourt PL, Pase THS, Toazza MR, de Mattos AA, Alliance of Brazilian Centers for Cirrhosis Care – the ABC Group

ORIGINAL ARTICLE

Basic Study

- 4787 Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional *in vitro* models

Monzer A, Wakimian K, Ballout F, Al Bitar S, Yehya A, Kanso M, Saheb N, Tawil A, Doughan S, Hussein M, Mukherji D, Faraj W, Gali-Muhtasib H, Abou-Kheir W

Case Control Study

- 4812 Previous hepatitis B viral infection—an underestimated cause of pancreatic cancer

Batskikh S, Morozov S, Dorofeev A, Borunova Z, Kostyushev D, Brezgin S, Kostyusheva A, Chulanov V

Retrospective Cohort Study

- 4823 Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study

Hahn GD, LeBlanc JF, Golovics PA, Wetwittayakhleng P, Qatomah A, Wang A, Boodaghians L, Liu Chen Kiow J, Al Ali M, Wild G, Afif W, Bitton A, Lakatos PL, Bessissow T

Retrospective Study

- 4834 Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease

Gordon BL, Galati JS, Yang S, Longman RS, Lukin D, Scherl EJ, Battat R

- 4846 Development and validation of a risk prediction score for the severity of acute hypertriglyceridemic pancreatitis in Chinese patients

Liu ZY, Tian L, Sun XY, Liu ZS, Hao LJ, Shen WW, Gao YQ, Zhai HH

Observational Study

- 4861** Are bowel symptoms and psychosocial features different in irritable bowel syndrome patients with abdominal discomfort compared to abdominal pain?

Fang XC, Fan WJ, Drossman DD, Han SM, Ke MY

Randomized Clinical Trial

- 4875** Peroral endoscopic myotomy *vs* laparoscopic myotomy and partial fundoplication for esophageal achalasia: A single-center randomized controlled trial

de Moura ETH, Jukemura J, Ribeiro IB, Farias GFA, de Almeida Delgado AA, Coutinho LMA, de Moura DTH, Aissar Sallum RA, Nasi A, Sánchez-Luna SA, Sakai P, de Moura EGH

SYSTEMATIC REVIEWS

- 4890** Chinese herbal formula shen-ling-bai-zhu-san to treat chronic gastritis: Clinical evidence and potential mechanisms

Jin W, Zhong J, Song Y, Li MF, Song SY, Li CR, Hou WW, Li QJ

SCIENTOMETRICS

- 4909** Global research trends in the field of liver cirrhosis from 2011 to 2020: A visualised and bibliometric study

Gan PL, Huang S, Pan X, Xia HF, Zeng XY, Ren WS, Zhou X, Lv MH, Tang XW

CASE REPORT

- 4920** Ectopic bronchogenic cyst of liver misdiagnosed as gallbladder diverticulum: A case report

Dong CJ, Yang RM, Wang QL, Wu QY, Yang DJ, Kong DC, Zhang P

LETTER TO THE EDITOR

- 4926** Prediction of moderately severe and severe acute pancreatitis in pregnancy: Several issues

Yang QY, Hu JW

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Osamu Toyoshima, MD, PhD, Director, Department of Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo 157-0066, Japan. t@ichou.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*, Production Department Director: *Xiang Li*, Editorial Office Director: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

September 7, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Observational Study

Are bowel symptoms and psychosocial features different in irritable bowel syndrome patients with abdominal discomfort compared to abdominal pain?

Xiu-Cai Fang, Wen-Juan Fan, Douglas D Drossman, Shao-Mei Han, Mei-Yun Ke

Specialty type: Gastroenterology and hepatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Caballero-Mateos AM, Spain; Losurdo G, Italy

Received: January 19, 2022

Peer-review started: January 19, 2022

First decision: April 10, 2022

Revised: April 19, 2022

Accepted: August 6, 2022

Article in press: August 6, 2022

Published online: September 7, 2022



Xiu-Cai Fang, Wen-Juan Fan, Mei-Yun Ke, Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Wen-Juan Fan, Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, Hubei Province, China

Douglas D Drossman, Center of Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC 27517, United States

Douglas D Drossman, Center for Education and Practice of Biopsychosocial Care, Drossman Gastroenterology, Durham, NC 27713, United States

Douglas D Drossman, Rome Foundation, Rome Foundation, Raleigh, NC 27614, United States

Shao-Mei Han, Department of Epidemiology and Statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing 100005, China

Corresponding author: Xiu-Cai Fang, MD, Professor, Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China. fangxiuca2@aliyun.com

Abstract

BACKGROUND

The Rome IV criteria eliminated abdominal discomfort for irritable bowel syndrome (IBS), which was previously included in Rome III. There are questions as to whether IBS patients with abdominal discomfort (seen in Rome III but not Rome IV) are different from those with abdominal pain (Rome IV).

AIM

To compare bowel symptoms and psychosocial features in IBS patients diagnosed with Rome III criteria with abdominal discomfort, abdominal pain, and pain & discomfort.

METHODS

We studied IBS patients meeting Rome III criteria. We administered the IBS symptom questionnaire, psychological status, and IBS quality of life. Patients were classified according to the predominant abdominal symptom associated with defecation into an only pain group, only discomfort group, and pain & discomfort group. We compared bowel symptoms, extraintestinal symptoms, IBS quality of life, psychological status and healthcare-seeking behaviors, and efficacy among the three groups. Finally, we tested risk factors for symptom reporting in IBS patients.

RESULTS

Of the 367 Rome III IBS patients enrolled, 33.8% (124 cases) failed to meet Rome IV criteria for an IBS diagnosis. There were no meaningful differences between the pain group ($n = 233$) and the discomfort group ($n = 83$) for the following: (1) Frequency of defecatory abdominal pain or discomfort; (2) Bowel habits; (3) Coexisting extragastrointestinal pain; (4) Comorbid anxiety and depression; and (5) IBS quality of life scores except more patients in the discomfort group reported mild symptom than the pain group (22.9% *vs* 9.0%). There is a significant tendency for patients to report their defecatory and non-defecatory abdominal symptom as pain alone, or discomfort alone, or pain & discomfort (all $P < 0.001$).

CONCLUSION

IBS patients with abdominal discomfort have similar bowel symptoms and psychosocial features to those with abdominal pain. IBS symptoms manifesting abdominal pain or discomfort may primarily be due to different sensation and reporting experience.

Key Words: Irritable bowel syndrome; Abdominal pain; Abdominal discomfort; Diagnosis; Psychosocial distress; Quality of life

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: It is generally accepted that abdominal pain is the most predominant symptom of irritable bowel syndrome (IBS), and Rome IV eliminated abdominal discomfort as diagnostic criteria for IBS. Asian studies showed about one-third of IBS patients diagnosed using Rome III criteria had abdominal discomfort alone. In this study, we compared bowel symptoms, extraintestinal symptoms, IBS-quality of life, psychological status and healthcare-seeking behaviors, and efficacy between the abdominal pain and abdominal discomfort groups expecting to find a difference between the two groups but did not. We also assessed risk factors for symptom reporting for IBS patients.

Citation: Fang XC, Fan WJ, Drossman DD, Han SM, Ke MY. Are bowel symptoms and psychosocial features different in irritable bowel syndrome patients with abdominal discomfort compared to abdominal pain? *World J Gastroenterol* 2022; 28(33): 4861-4874

URL: <https://www.wjgnet.com/1007-9327/full/v28/i33/4861.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v28.i33.4861>

INTRODUCTION

Irritable bowel syndrome (IBS) is a common functional bowel disorder with a global prevalence of 4.1% according to the Rome IV criteria and 10.1% with Rome III criteria[1]. Using the Rome III definition, IBS is characterized by recurrent abdominal pain or discomfort associated with altered bowel frequency or stool form[2]. However, the term “discomfort” was deleted from the 2016 Rome IV diagnostic criteria because some languages do not have a word for discomfort or it has different meanings in different languages or cultures[3,4]. Possibly abdominal discomfort has qualitative and quantitative levels of distinction with abdominal pain[5]. The data from a population-based survey of adults in the United States, Canada, and the United Kingdom showed that eliminating “discomfort” from the criteria for IBS affected diagnostic rates only slightly[6], and only 10% of Rome III-IBS patients among the Swedish cohort did not fulfill Rome-IV IBS diagnosis due to reporting only abdominal discomfort and not pain [7]. However, clinical studies from Thailand and central China revealed that about one-third of patients with IBS diagnosed using Rome III criteria had abdominal discomfort alone[8,9]. This rate is as high as 84.2% from another clinical retrospective report from Tianjin, China[10]. Evidence regarding pathophysiological differences between abdominal pain and abdominal discomfort such as whether these symptoms are categorically different or exist on a continuum of severity is lacking[11,12]. It is also unclear whether there are clinical or phenotypical distinctions with IBS presenting with abdominal pain

vs abdominal discomfort as to how this change of criteria impacts the clinical practice.

This study aimed to: (1) Compare the bowel and extraintestinal symptoms of patients with IBS presenting with abdominal discomfort alone to those with pain alone as well as with pain & discomfort; (2) Evaluate the anxiety, depression, quality of life (QOL), and symptom reporting tendency for patients with pain and discomfort; and (3) Validate whether the discomfort is milder than pain on a continuum of severity for Chinese patients. The clinical data were drawn from the IBS database of Peking Union Medical College Hospital.

MATERIALS AND METHODS

Subjects

Consecutive patients with IBS aged 18–65 years from Peking Union Medical College Hospital gastroenterology clinics were enrolled in this study from June 2009 to February 2016. All patients met Rome III diagnostic and subtype criteria[2], including IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS. Patients with organic gastrointestinal diseases and metabolic diseases were excluded based on the results of routine tests for blood, urine, stool; liver, kidney, and thyroid function, measurements of carcinoembryonic antigen, erythrocyte sedimentation rate, and C-reactive protein, and abdominal ultrasound and colonoscopy/barium enema in the past year. The participating patients provided oral or written consent to participate before study enrollment. This study was approved by the Peking Union Medical College Hospital Ethics Committee (S-234).

IBS symptom questionnaire

The IBS symptom questionnaire was administered by well-trained investigators in face-to-face interviews. The questionnaire was adapted from a previous symptom-related questionnaire for adult functional gastrointestinal disorders in Beijing[13], the Rome III diagnostic questionnaire for adult functional gastrointestinal disorders, and the Rome III psychosocial alarm questionnaire for functional gastrointestinal disorders[2]. Information collected included demographic data, IBS disease course, frequency and severity of IBS symptoms, defecation-related symptoms, extraintestinal symptoms, physical examination and supplementary examination results, and IBS treatments in the whole disease course and the last year.

Patients were evaluated according to abdominal pain, abdominal discomfort, or both abdominal pain & discomfort just before defecation (pre-defecatory), at IBS onset, and between IBS symptom episodes without association to defecation (ordinary). Patients with the presence or worsening of pre-defecatory abdominal pain and without pre-defecatory abdominal discomfort were categorized as the pain group regardless of whether they had abdominal pain or discomfort during the ordinary period. Similarly, patients with pre-defecatory abdominal discomfort and without pre-defecatory abdominal pain were categorized as the discomfort group, and patients with pre-defecatory abdominal pain and discomfort were categorized as the pain & discomfort group.

The main intestinal symptom score for IBS-D was calculated according to the report by Zhu *et al*[14]. Diagnosis of gastroesophageal reflux disease and functional dyspepsia were made according to the Montreal consensus[15] and Rome III diagnostic and subtype criteria[2], respectively. Patients who did not meet Rome IV diagnostic criteria for IBS (including patients with pre-defecatory abdominal discomfort alone or symptom frequency < 1 d/wk) were evaluated for possible diagnoses of other functional bowel disorders using Rome IV criteria, including functional diarrhea, functional constipation, functional abdominal bloating/distension, and unspecified functional bowel disorder[3].

QOL evaluation

The simplified Chinese version of the IBS-QOL instrument was used to evaluate patient QOL[16], which was translated from IBS-QOL[17] and well validated. This instrument was completed by patients according to the instructions provided; the total score and eight domain scores were calculated as in a previous publication[14].

Psychological evaluation

The Hamilton Anxiety (HAMA) and Hamilton Depression (HAMD) scales were used to evaluate patient psychological status by specially trained professionals through conversation and observation. A HAMA score ≥ 14 was judged as anxiety and ≥ 21 as moderate-to-severe anxiety. A HAMD score ≥ 17 was judged as depression and ≥ 24 as moderate-to-severe depression[18,19].

Statistical analysis

All analyses were performed using SPSS version 19.0 (IBM Corporation, Somers, NY, United States). Parametric distribution was evaluated by Kolmogorov-Smirnov test. Parametric and categorical data are presented as mean \pm SD or rate, respectively. Nonparametric data were presented as median and interquartile range. Comparisons among the three groups were made by one-way analysis of variance

for parametric data, Kruskal-Wallis test for nonparametric data, and χ^2 test for categorical variables. Spearman's test was performed to assess nonparametric correlations between two quantitative variables. Bonferroni test was used to adjust for pairwise comparison among the three groups after analysis of variance. Multiple logistic regression analysis was used to determine the independent factors for abdominal pain or abdominal discomfort. $P < 0.05$ was considered statistically significant.

RESULTS

Demographic data

In total, 367 patients meeting Rome III criteria for IBS were enrolled in this study (205 males and 162 females), with an average age of 43.0 ± 11.4 years.

There were 233 patients (63.5%) in the pain group, 83 patients (22.6%) in the discomfort group, and 51 patients (13.9%) in the pain & discomfort group. There were more males in the discomfort group than in the pain group (67.5% *vs* 50.2%, $P = 0.01$). There were no significant differences in age, body mass index, educational level, physical work, family economic status, marriage status, the average IBS disease course, and IBS subtype distribution among the three groups ($P > 0.05$) (Table 1).

Characteristics of abdominal pain, discomfort, and pain & discomfort

In the three groups, the locations of abdominal pain, discomfort, or pain & discomfort before defecation were mainly in the umbilical region, lower abdomen, and left lower quadrant. There was no significant difference in distribution of symptom location, even though more patients in the discomfort group reported the symptom location as "others" (indicating varied or obscure locations) than in the pain group (21.7% *vs* 10.3%, $P = 0.009$). There was a significant difference in the severity of pain and/or discomfort among the three groups ($P = 0.007$), and more patients in the discomfort group reported mild symptom than those in the pain group. There was no significant difference in frequency among the three groups (Table 2).

There were significant differences in the prevalence of ordinary abdominal pain or/and discomfort among the three groups ($P < 0.001$). More patients in the pain group reported ordinary abdominal pain than those in the discomfort group and pain & discomfort group, while more patients in the discomfort group reported ordinary abdominal discomfort than those in the pain group and pain & discomfort group. In the pain & discomfort group, 54.9% of patients reported having ordinary pain and discomfort, which was significantly higher than the other two groups (Table 2).

In total, there were 52 patients (14.2%) with onset frequency of < 1 d/wk (*i.e.* 3 d/mo), including 37 cases in the pain group, 11 cases in the discomfort group, and 4 cases in the pain & discomfort group. The proportion of less frequency was 15.9%, 13.3%, and 7.8%, respectively, without significant difference ($P = 0.32$). According to Rome IV diagnostic criteria, a total of 124 patients (33.8%) would not meet an IBS diagnosis (Figure 1).

Bowel movements and stool form

In 345 patients with IBS-D, the average bowel movements during symptom non-onset period of the pain group (1.5 ± 0.9 /d) were less than the discomfort group (1.8 ± 1.1 /d) and the pain & discomfort group (1.9 ± 1.1 /d) ($P = 0.004$), but there were no significant differences in average bowel movements during symptom onset period (3.8 ± 1.5 *vs* 3.8 ± 1.4 *vs* 3.6 ± 1.5 , $P > 0.05$) (Figure 2A). There were no significant differences in stool form during symptom non-onset and onset periods among the three groups (all $P > 0.05$) (Figure 2B).

Abdominal pain and/or discomfort improvement after defecation

Abdominal pain and/or discomfort improved after defecation except for 1 patient in the pain group. There was no significant difference in the waiting time and degree for improvement among the three groups (Figure 2C and D).

In IBS-D patients, the main intestinal symptom score was 9.3 ± 1.6 in the pain group, 9.4 ± 1.5 in the discomfort group, and 9.6 ± 1.3 in the pain & discomfort group ($P > 0.05$).

Defecation-related symptoms

The prevalence of defecation related symptoms such as abdominal bloating, urgency, sensation of incomplete evacuation, and passing mucus were high overall for all 3 groups. More patients in the discomfort group reported having urgency, sensation of incomplete evacuation, and passing mucus than those in the pain group (all $P < 0.05$). In the pain & discomfort group, the prevalence of abdominal bloating, abdominal distension, and anorectal pain was significantly higher than that in the pain group (all $P < 0.05$) (Table 2).

Extraintestinal symptoms

There were no significant differences in the prevalence of gastroesophageal reflux disease or functional


Table 1 Demographic data for irritable bowel syndrome patients with abdominal pain alone, abdominal discomfort alone, and abdominal pain & discomfort

Variable	Pain group (n = 233)	Discomfort group (n = 83)	Pain & discomfort group (n = 51)	P value
Male, %	117 (50.2)	56 (67.5)	32 (62.7)	0.01 ²
Age in yr	43.7 ± 11.7	42.3 ± 10.6	40.8 ± 11.0	0.23
BMI in kg/m ²	23.0 ± 4.0	22.8 ± 4.0	22.3 ± 3.8	0.56
Education level, college and above, %	71 (30.5)	29 (34.9)	13 (25.5)	0.51
Physical labor, %	135 (57.9)	42 (50.6)	34 (66.7)	0.18
Family economic status, well-off & above, %	105 (45.1)	44 (53.0)	18 (35.3)	0.13
Marriage status, married, %	201 (86.3)	71 (85.5)	41 (80.4)	0.56
IBS disease course in yr ¹	6.0 (7.5)	5.3 (7.0)	6.0 (7.0)	0.38
IBS type				0.06
IBS-D, %	95.7	96.4	86.3	
IBS-C, %	3.0	2.4	7.8	
IBS-M, %	1.3	1.2	5.9	

¹Data presented as median (interquartile range), Kruskal-Wallis test. Note: P value is the difference among pain group, discomfort group, and pain & discomfort group, superscript letter is significantly different at a $P < 0.05$.

²The difference is between the pain group and discomfort group.

Data presented as number (%) or mean ± SD. Analysis of variance and χ^2 tests. IBS-D: Irritable bowel syndrome with diarrhea; BMI: Body mass index; IBS-C: Irritable bowel syndrome with constipation; IBS-M: Mixed irritable bowel syndrome.



DOI: 10.3748/wjg.v28.i33.4861 Copyright ©The Author(s) 2022.

Figure 1 Constitution diagram of irritable bowel syndrome patients diagnosed with Rome III and Rome IV criteria. About one-third of irritable bowel syndrome patients (parts dragged out of ring) diagnosed with Rome III criteria failed in irritable bowel syndrome diagnosis with Rome IV criteria because of only having abdominal discomfort before defecation (in green, 22.6%) or frequency of abdominal pain less than 1 d/wk (in light colors, 14.2%), which 3% of patients among them have discomfort alone with less frequency (in light green). IBS: Irritable bowel syndrome.

dyspepsia between the pain group and the discomfort group ($P > 0.05$), but the prevalence of epigastric pain syndrome, mainly epigastric pain was higher in the pain group than the discomfort group (21.0% vs 7.2%, 18.5% vs 6.0%, $P < 0.05$). More patients in the pain & discomfort group reported early satiation, dyspareunia, and menstrual pain for women than in the pain group (all $P < 0.05$). The prevalence of dyspareunia in the pain & discomfort group was also higher than in the discomfort group ($P < 0.001$) (Table 3).

Comorbid anxiety and depression

There were no significant differences in HAMA score, HAMD score, or the prevalence and severity of anxiety and depression among the three groups (Table 4).

IBS-QOL

The QOL of patients with IBS showed an obvious decrease with an IBS-QOL score of 72.2 ± 17.9 in the

Table 2 Characteristics of bowel symptoms in irritable bowel syndrome patients with abdominal pain alone, abdominal discomfort alone, and abdominal pain & discomfort

Variable	Pain group (n = 233)	Discomfort group (n = 83)	Pain & discomfort group (n = 51)	P value
Location ¹ , %				0.213
Left lower quadrant	67 (28.8)	14 (16.9)	12 (23.5)	
Umbilical	79 (33.9)	27 (32.5)	20 (39.2)	
Lower abdomen	65 (27.9)	23 (27.7)	15 (29.4)	
Epigastric	11 (4.7)	2 (2.4)	2 (3.9)	
Whole abdomen	12 (4.0)	8 (9.6)	5 (9.8)	
Others	24 (10.3)	18 (21.7)	7 (13.7)	
Severity, %				0.007
Mild	21 (9.0)	19 (22.9)	6 (11.7)	
Moderate	160 (68.7)	55 (66.3)	37 (72.6)	
Severe	52 (22.3)	9 (10.8)	8 (15.7)	
Frequency, %				0.290
3 d/mo	37 (15.9)	11 (13.3)	4 (7.84)	
1 d/wk	25 (10.7)	5 (6.0)	2 (3.9)	
>1 d/wk	108 (46.4)	38 (45.8)	27 (52.94)	
Every day	63 (27.0)	29 (34.9)	18 (35.3)	
Ordinary pain/discomfort, %				< 0.001
Pain alone	84 (36.1)	6 (7.2)	6 (11.8)	
Discomfort alone	21 (9.0)	43 (51.8)	3 (5.9)	
Pain & discomfort	7 (3.0)	2 (2.4)	28 (54.9)	
No pain or discomfort	121 (51.9)	32 (38.6)	14 (27.4)	
Defecation-related symptoms, %				
Abdominal bloating	93 (39.9)	43 (51.8)	35 (68.6)	0.001 ³
Abdominal distension	21 (9.0)	13 (15.7)	12 (23.5)	0.01 ³
Urgency	197 (84.6)	80 (96.4)	42 (82.4)	0.01 ^{2,4}
Defecation straining	70 (30.0)	25 (30.1)	23 (45.1)	0.10
Sensation of anorectal obstruction	62 (26.6)	30 (36.1)	19 (37.3)	0.13
Anorectal pain	28 (12.0)	15 (18.1)	17 (33.3)	0.001 ³
Sensation of incomplete evacuation	164 (70.4)	74 (89.2)	39 (76.5)	0.003 ²
Passing mucus	141 (60.5)	66 (79.5)	39 (76.5)	0.002 ²

¹Some patients reported more than one location. χ^2 test, data presented as number (%).

²The difference is between pain group and discomfort group.

³The difference is between pain group and pain & discomfort group.

⁴The difference is between discomfort group and pain & discomfort group.

P value is the difference among pain group, discomfort group, and pain & discomfort group, and superscript letters are significantly different at a $P < 0.05$.

pain group, 72.0 ± 20.0 in the discomfort group, and 70.4 ± 15.0 in the pain & discomfort group while comparing to the mean overall score in healthy Chinese subjects (95.50 ± 6.73 with the scores on each of the eight domains being ≥ 90.00)[16]. The most meaningful impairment for all 3 groups was food avoidance, following by dysphoria, interference with activity, and health worry. There were no significant differences in the eight domain scores between the pain group and discomfort group (Figure 3), while patients in the pain & discomfort group had lower QOL than patients having discomfort alone ($P = 0.03$).

Table 3 Coexisting extraintestinal symptoms of irritable bowel syndrome patients with abdominal pain alone, abdominal discomfort alone, and abdominal pain & discomfort

Variable	Pain group (n = 233)	Discomfort group (n = 83)	Pain & discomfort group (n = 51)	P value
GERD, %	60 (25.8)	14 (16.9)	10 (19.6)	0.20
Heartburn	35 (15.0)	6 (7.2)	6 (11.8)	0.18
Acid reflux	44 (18.9)	10 (12.1)	5 (9.8)	0.15
Food regurgitation	14 (6.0)	4 (4.8)	3 (5.9)	0.92
Retrosternal chest pain	10 (4.3)	3 (3.6)	2 (3.9)	0.96
Functional dyspepsia, %	86 (36.9)	23 (27.7)	18 (35.3)	0.32
Epigastric pain syndrome	49 (21.0)	6 (7.2)	7 (13.7)	0.01 ²
Epigastric pain	43 (18.5)	5 (6.0)	7 (13.7)	0.02 ²
Epigastric burning	12 (5.2)	2 (2.4)	3 (5.9)	0.54
Postprandial distress syndrome	64 (27.5)	22 (26.5)	15 (29.4)	0.94
Postprandial fullness	57 (24.5)	20 (24.1)	9 (17.7)	0.57
Early satiation	14 (6.0)	6 (7.2)	9 (17.7)	0.02 ³
Somatic pain, %				
Headache	17 (45.9)	37 (44.6)	26 (51.0)	0.76
Neck pain	21 (9.0)	7 (8.4)	3 (5.9)	0.77
Backache	41 (17.6)	8 (9.6)	7 (13.7)	0.21
Dyspareunia	12 (5.2)	6 (7.2)	11 (21.6)	< 0.001 ^{3,4}
Menstrual pain ¹	30 (25.9)	10 (37.0)	11 (57.9)	0.016 ³

¹The number of female patients in the abdominal pain, abdominal discomfort, and pain & discomfort groups was 116, 27, and 19, respectively. χ^2 test. Data presented as number (%).

²P value is difference between the pain group and the discomfort group.

³The difference is between the pain group and the pain & discomfort group.

⁴The difference is between the discomfort group and the pain & discomfort group.

P value is the difference among the pain group, discomfort group, and pain & discomfort group, and superscript letters are significantly different at $P < 0.05$. GERD: Gastroesophageal reflux disease.

Healthcare-seeking behaviors and efficacy

There were no significant differences among the three groups in the average number of consultations and colonoscopies in the whole disease course and the average consultations and intermittent and long-term medication use in the last year (all $P > 0.05$). More patients in discomfort group used antispasmodics (muscarinic cholinergic receptor antagonists and selective intestinal calcium channel blockers), and all patients who used the antispasmodics had a reasonably good response (response rate over 50%). The overall satisfaction rate (including complete satisfaction and satisfaction) with medical care showed no significant difference among the three groups ($P > 0.05$) (Table 5).

Risk factors for IBS patients describing pre-defecatory symptoms as abdominal pain alone, discomfort alone, and pain & discomfort

Twelve variables differing between the pain group and the discomfort group at a P value with significant difference in Tables 1-3 were utilized for a multiple logistic regression analysis. We found that male patients [odds ratio (OR) = 1.955, 95% confidence interval (CI): 1.104-3.462, $P = 0.021$] and patients with mild defecatory abdominal pain or discomfort (OR = 4.020, 95% CI: 1.436-11.253, $P = 0.008$) were the predictors for patients to describe their pre-defecatory symptoms as abdominal discomfort alone rather than abdominal pain alone (Table 6). Similar analyses were performed between the pain group and the pain & discomfort group (11 variables) and the discomfort group and the pain & discomfort group (10 variables). We found that abdominal bloating (OR = 2.238, 95% CI: 1.080-4.638, $P = 0.030$) and anorectal pain (OR = 2.979, 95% CI: 1.347-6.585, $P = 0.007$) were the predictors for patients to describe their symptom as pain & discomfort rather than pain alone (Table 6), and no predictors were found for patients to describe their symptom as discomfort alone or pain & discomfort.

Table 4 Comorbid anxiety and depression among irritable bowel syndrome patients with abdominal pain alone, abdominal discomfort alone, and abdominal pain & discomfort

Variable	Pain group (n = 233)	Discomfort group (n = 83)	Pain & discomfort group (n = 51)	P value
HAMA score	16.1 ± 7.3	15.5 ± 7.3	17.3 ± 7.4	0.36
Comorbid anxiety, %	141 (60.5)	49 (59.0)	38 (74.5)	0.14
Mild	69 (29.6)	25 (30.1)	21 (41.2)	0.26
Moderate-severe	72 (30.9)	24 (28.9)	17 (33.3)	0.86
HAMD score	13.2 ± 6.2	12.3 ± 6.1	14.3 ± 5.5	0.18
Comorbid depression, %	66 (28.3)	22 (26.5)	18 (35.3)	0.53
Mild	54 (23.2)	20 (24.1)	17 (33.3)	0.31
Moderate-severe	12 (5.2)	2 (2.4)	1 (2.0)	0.40
Comorbid anxiety & depression, %	62 (26.6)	20 (24.1)	18 (35.3)	0.35

Data presented as mean ± SD or number (%). Student's *t* test and χ^2 tests. *P* value is difference among the pain group, discomfort group, and pain & discomfort group. HAMA: Hamilton Anxiety Scale; HAMD: Hamilton Depression Scale.

Table 5 Consultations and medications of irritable bowel syndrome patients with abdominal pain alone, abdominal discomfort alone, and abdominal pain & discomfort

Variable	Pain group (n = 233)	Discomfort group (n = 83)	Pain & discomfort group (n = 51)	P value
In the whole disease course				
Consultation times per year ¹	4.6 ± 6.7	5.7 ± 6.2	4.2 ± 4.1	0.54
Colonoscopies ²	1.9 ± 1.4	1.5 ± 0.8	1.6 ± 0.9	0.22
In the last year				
Consultation times ¹	4.0 ± 5.7	4.5 ± 4.5	4.9 ± 4.7	0.54
Medications, intermittent and long-term use, %	164 (70.4)	56 (67.5)	43 (84.3)	0.09
Antispasmodics use				
Use rate	29 (12.4)	24 (28.9)	12 (23.5)	0.002 ³
Response rate	22 (75.9)	13 (54.2)	10 (83.3)	0.12
Overall satisfaction to medical care, %	125 (53.7)	39 (47.0)	21 (41.2)	0.21

¹Consultation times were average consultation times of consultants.

²Colonoscopies were average colonoscopies of patients who performed colonoscopies.

³The difference is between the pain group and the discomfort group.

Data presented as mean ± SD or number (%). Analysis of variance and χ^2 test. *P* value is difference among pain group, discomfort group, and pain & discomfort group, and superscript letter is significantly different at a *P* < 0.05.

Diagnosis of patients with abdominal discomfort alone according to Rome IV criteria

Among 83 patients having pre-defecatory abdominal discomfort alone and not meeting Rome IV criteria for IBS, 48 patients (57.8%) met the diagnosis for functional diarrhea, 28 patients (33.7%) for functional abdominal bloating/distension, 2 patients (2.4%) for functional constipation, and 5 patients (6.0%) were classified as unspecified functional bowel disorder.

DISCUSSION


The present study comprehensively compared the bowel symptoms and psychosocial features of IBS

Table 6 Risk factors for irritable bowel syndrome patients describing symptoms as abdominal pain alone, abdominal discomfort alone, and abdominal pain & discomfort

	Partial regression coefficient	Standard error	Wald χ^2	95%CI	P value
Abdominal discomfort alone <i>vs</i> abdominal pain alone					
Male sex	0.671	0.291	5.293	1.955 (1.104-3.462)	0.021 ^a
Severity (mild defecatory pain or discomfort)	1.391	0.525	7.018	4.020 (1.436-11.253)	0.008 ^a
Abdominal pain alone <i>vs</i> abdominal pain & discomfort					
Abdominal bloating	0.805	0.372	4.692	2.238 (1.080-4.638)	0.030 ^a
Anorectal pain	1.091	0.405	7.272	2.979 (1.347-6.585)	0.007 ^a

^a $P < 0.05$. Multiple logistic regression analysis. Superscript letter is significantly different at a $P < 0.05$.

CI: Confidence interval.



DOI: 10.3748/wjg.v28.i33.4861 Copyright ©The Author(s) 2022.

Figure 2 Comparison of bowel movements and stool forms in irritable bowel syndrome with diarrhea patients and improvement of abdominal pain or discomfort after defecation in irritable bowel syndrome patients among the abdominal pain alone, abdominal discomfort alone, and abdominal pain & discomfort groups. A: Bowel movements during irritable bowel syndrome with diarrhea non-onset and onset status; B: Stool forms based on Bristol Stool Form Scale during irritable bowel syndrome with diarrhea non-onset and onset status; C: Degree of improvement of abdominal pain and discomfort with defecation; D: Waiting time for improvement of abdominal pain and discomfort with defecation in irritable bowel syndrome patients. Numbers in the column are percentages. ^b $P < 0.01$. BM: Bowel movement.

patients with pre-defecatory abdominal pain alone to pre-defecatory abdominal discomfort alone, and abdominal pain & discomfort. We found that patients with abdominal discomfort had similar bowel and extraintestinal symptoms, comorbid anxiety and depression, QOL, and healthcare-seeking behaviors to those with abdominal pain.

It is generally accepted that abdominal pain is the most predominant symptom of IBS[3]; however, a previous clinical study from the United States found only 21% of IBS patients with moderate to severe symptoms reported their predominant symptom in terms of abdominal pain[11]. Another study conducted by Lembo *et al*[12] showed that the proportions of IBS patients who reported pain or gas




Figure 3 Comparison of irritable bowel syndrome-quality of life. There were no significant differences in the total score and eight domain scores among the three groups. Numbers in the column are percentages. IBS-QOL: Irritable bowel syndrome-quality of life.

(bloating-type discomfort) as one of their viscerosensory symptoms were similar (60% *vs* 66%). Currently, several studies compared the diagnostic rate between Rome III and IV criteria for IBS in the general population and consulting cohorts. The proportions of having abdominal discomfort varied among the western countries (2.4%-9.9%)[6,7,20,21] and the eastern countries (29.8%-84.2%)[8-10]. In this study, IBS patients with abdominal discomfort accounted for 22.6%. The elimination of abdominal discomfort from the diagnostic criteria had little effect on the diagnosis of IBS for the western countries [3], while a significant proportion of IBS patients were no longer IBS in Asian, including in China[8-10].

The significant difference between the western and eastern countries indicates there may be cultural factors that affect the experience and reporting of abdominal symptoms. The definition of abdominal pain is more uniformly accepted, while the definition for abdominal discomfort is ambiguous; “discomfort means an uncomfortable sensation not described as pain” according to the Rome III criteria[2]. Further, there are no comparison studies concerning abdominal discomfort descriptions in cross-cultural cohorts. In this study, Chinese patients with IBS accurately reported abdominal discomfort, including the location and association with defecation (both in pre-defecatory and non-defecatory periods), as well as other defecation related symptoms (*i.e.* urgency and so on). Symptom characteristics were similar with abdominal pain, which indicated that abdominal discomfort was a relatively explicit symptom for Chinese patients, unlike the impression from a cognitive study from American IBS patients [6] in which abdominal discomfort might encompass a wide range of symptoms such as bloating, gas, fullness, flatulence, sensation of incomplete evacuation, and urgency.

Abdominal pain and discomfort are both visceral perceptions of abnormality on the same continuum with pain appearing at the more severe end of the spectrum[11]. In this study, there were no meaningful differences between the pain alone group and discomfort alone group in frequencies as well as the main intestinal symptom score for IBS-D patients except more patients in the discomfort group reported mild symptoms than the pain group. In addition, we found patients with mild defecatory abdominal pain or discomfort were predisposed to describe their pre-defecatory symptoms as abdominal discomfort alone rather than abdominal pain alone, which indicated abdominal discomfort may appear as the milder form of pain. However, it was reported that more IBS patients rank abdominal discomfort as their most bothersome symptom than abdominal pain (60% *vs* 29% in America[12], 15.3% *vs* 4.5% of IBS-C in Japan [22]), and the severity of abdominal discomfort had the strongest independent relationship with QOL impairment[10]. Patients in the three groups had similar healthcare-seeking behavior and satisfaction to medical care in this study. We speculated in terms of the symptom itself, the overall severity of IBS, and occupation of medical resources that abdominal discomfort is as important as abdominal pain.

Nevertheless, more patients in the discomfort group reported accompanying urgency, sensation of incomplete evacuation, and passing mucus than the pain group. Patients with abdominal pain & discomfort had a higher prevalence of abdominal bloating/distension and anorectal pain than patients with abdominal pain alone, and a lower score of QOL than patients with abdominal discomfort alone. In addition, we found that abdominal bloating and anorectal pain were the predictors for patients to describe their symptom as pain & discomfort rather than pain alone, suggesting coexisting symptoms played important roles in the generation of discomfort feeling.

We noticed that the previous studies seldom paid attention to the abdominal symptoms of IBS patients during non-defecatory period. An interesting finding in this study is more patients having pre-defecatory abdominal discomfort alone also reported non-defecatory abdominal discomfort than the other two groups, and a similar report tendency for patients with pain alone and pain & discomfort

during defecatory period and non-defecatory period. In terms of extraintestinal symptoms, more patients in the pain group reported coexisting epigastric pain. The possible explanation for this reporting tendency is individual sensation and reporting experience to the similar stimulations and pathophysiological changes[11].

The relationships between diary stress, psychological distress, and severity of abdominal discomfort symptoms in women with IBS have been noted[23]. In this study, the scores of HAMA and HAMD and comorbid anxiety and depression were comparable between the pain group and the discomfort group. The impact of mental status to the symptom sensation and reporting could be ignored.

To date, studies on the pathophysiology of IBS mainly focused on abdominal pain[12,24-27]. As far as we know, there was no direct evidence focused on mechanism of abdominal discomfort or comparison of the difference of pathogenesis between abdominal pain and discomfort. Abdominal discomfort could simultaneously improve with abdominal pain and/or bloating to antispasmodics tiotropium and octylonium, secretagogue linaclotide, or simethicone and *Bacillus coagulans* for IBS or IBS-C patients[28-31]. It is unclear whether the treatments focused on bloating, diarrhea, or constipation could relieve the abdominal discomfort for those patients having defecatory abdominal discomfort alone while they are diagnosed as other bowel disorders according to Rome IV criteria (as shown in the results). Therefore, we realized that it may be more beneficial to classify patients with bowel-related abdominal discomfort into IBS from a therapeutic consideration.

There are several limitations in this study. We only included the IBS patients with typical changes of bowel habits, *i.e.* IBS-D and IBS-C. Therefore, some mixed IBS and IBS-unclassified patients might be missed[7,31]. We enrolled patients with Rome III criteria and did not concern the abdominal pain and discomfort during or soon after bowel movement. The proportion of Rome III suspected IBS patients with this kind of pain or discomfort was low (2.9% according to Bai *et al*[9]). Moreover, we did not ask patients to describe the difference between abdominal pain and discomfort. The data for response to therapies were retrospective recall, including prescription and over-the-counter. In addition, the prevalence of IBS in the general population for males was lower than females (4.1% *vs* 5.4%)[32], but an equal or higher ratio of male to female consulting patients was reported in clinical studies[9,14]. It is unclear whether male patients have more vigorous healthcare seeking behaviors or priority of medical care than female patients, but more female patients reported frequent consultations and colonoscopies during the whole disease course of IBS than male patients[33]. IBS-D is the predominant subtype, which accounted for 74.1% in the general population of South China[34] and 66.3% in consulting patients[31]. In addition, this was a single-center study.

CONCLUSION

Chinese patients with IBS can differentiate and report abdominal pain or/and abdominal discomfort as their key bowel symptom. The patients with abdominal discomfort had similar bowel symptoms and psychosocial features to those with abdominal pain. There is a tendency for IBS patients to report their defecatory and non-defecatory abdominal symptom as pain alone, discomfort alone, or pain and discomfort. Pre-defecatory abdominal discomfort should be considered as an important symptom for IBS patients. Further studies focused on the pathophysiology and therapeutic response (including the cultural influence) of abdominal pain and discomfort are needed.

ARTICLE HIGHLIGHTS

Research background

The Rome IV criteria eliminated abdominal discomfort for irritable bowel syndrome (IBS), which was previously included in the Rome III criteria. Asian studies showed the rate of IBS patients with abdominal discomfort alone was high.

Research motivation

There are questions as to whether IBS patients with abdominal discomfort (seen in Rome III but not Rome IV) are different from those with abdominal pain (Rome IV).

Research objectives

To compare the bowel and extraintestinal symptoms of patients with IBS presenting with abdominal discomfort alone to those with pain alone as well as with pain & discomfort and to evaluate the anxiety, depression, quality of life, and symptom reporting tendency for patients with pain and discomfort.

Research methods

We enrolled IBS patients and collected their clinical data. Patients were classified to the pain only group,

the discomfort only group, and the pain & discomfort group. We compared bowel symptoms, extraintestinal symptoms, IBS-quality of life, psychological status and healthcare-seeking behaviors, and efficacy among the three groups and tested risk factors for symptom reporting in IBS patients.

Research results

About one-third of patients meeting Rome III criteria failed to meet Rome IV criteria for an IBS diagnosis. There were no meaningful differences between the pain group and discomfort group for frequency of defecatory abdominal pain or discomfort, bowel habits, coexisting extragastrointestinal pain, comorbid anxiety and depression, and IBS-quality of life scores.

Research conclusions

IBS patients with abdominal discomfort have similar bowel symptoms and psychosocial features to those with abdominal pain.

Research perspectives

Further studies focused on the pathophysiology and therapeutic response (including the cultural influence) of abdominal pain and discomfort are needed.

ACKNOWLEDGEMENTS

The authors thank their colleagues in the Department of Gastroenterology, Peking Union Medical College Hospital for their contributions to the enrollment of IBS patients.

FOOTNOTES

Author contributions: Fang XC was responsible for study concept and design, data collection and interpretation, and drafting and revision of the manuscript; Fan WJ participated in data collection, data analysis, and figure drafting; Drossman DD was responsible for critical revision; Han SM participated in data analysis; Ke MY participated in critical revision; all authors approved the final version of the manuscript as submitted.

Supported by the Program of International S & T Cooperation, No. 2014DFA31850; the National Natural Science Foundation of China, No. 81870379 and No. 81370488; and the Project of the National Key Technologies R & D Program in the 11th Five Year Plan period, No. 2007BAI04B01.

Institutional review board statement: This study was reviewed and approved by the Peking Union Medical College Hospital Ethics Committee, No. S-234.

Informed consent statement: All study participants provided oral or written consent to participate before study enrollment.

Conflict-of-interest statement: There are no conflicts of interest to report.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Xiu-Cai Fang 0000-0002-5600-8779; Wen-Juan Fan 0000-0002-2927-9266; Douglas D Drossman 0000-0002-8178-0453; Shao-Mei Han 0000-0003-2081-7969; Mei-Yun Ke 0000-0001-5793-9500.

S-Editor: Chen YL

L-Editor: Filipodia

P-Editor: Yuan YY

REFERENCES

- 1 **Sperber AD**, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, Kellow J, Okeke E, Quigley EMM, Schmulson M, Whorwell P, Archampong T, Adibi P, Andresen V, Benninga MA, Bonaz B, Bor S, Fernandez LB, Choi SC, Corazziari ES, Francisconi C, Hani A, Lazebnik L, Lee YY, Mulak A, Rahman MM, Santos J, Setshedi M, Syam AF, Vanner S, Wong RK, Lopez-Colombo A, Costa V, Dickman R, Kanazawa M, Keshteli AH, Khatun R, Maleki I, Poitras P, Pratap N, Stefanyuk O, Thomson S, Zeevenhoooven J, Palsson OS. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. *Gastroenterology* 2021; **160**: 99-114.e3 [PMID: [32294476](#) DOI: [10.1053/j.gastro.2020.04.014](#)]
- 2 **Drossman DA**, Corazziari E, Delvaux M. Rome III-functional gastrointestinal disorders. 3th ed. BW & A Books, inc: Durham, 2006
- 3 **Mearin F**, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. *Gastroenterology* 2016 [PMID: [27144627](#) DOI: [10.1053/j.gastro.2016.02.031](#)]
- 4 **Fang X**, Francisconi CF, Fukudo S, Gerson MJ, Kang JY, Schmulson W MJ, Sperber AD. Multicultural Aspects in Functional Gastrointestinal Disorders (FGIDs). *Gastroenterology* 2016 [PMID: [27144623](#) DOI: [10.1053/j.gastro.2016.02.013](#)]
- 5 **Spiegel BM**, Bolus R, Agarwal N, Sayuk G, Harris LA, Lucak S, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Talley J, Chang L. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. *Aliment Pharmacol Ther* 2010; **32**: 1275-1291 [PMID: [20955447](#) DOI: [10.1111/j.1365-2036.2010.04464.x](#)]
- 6 **Palsson OS**, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. *Gastroenterology* 2020; **158**: 1262-1273.e3 [PMID: [31917991](#) DOI: [10.1053/j.gastro.2019.12.021](#)]
- 7 **Aziz I**, Törnblom H, Palsson OS, Whitehead WE, Simrén M. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. *Am J Gastroenterol* 2018; **113**: 1017-1025 [PMID: [29880963](#) DOI: [10.1038/s41395-018-0074-z](#)]
- 8 **Patcharatrakul T**, Thanapirom K, Gonlachanvit S. Application of Rome III vs. Rome IV diagnostic criteria for irritable bowel syndrome (IBS) in clinical practice: is the newer the better? *Gastroenterology* 2017; **152**: S717
- 9 **Bai T**, Xia J, Jiang Y, Cao H, Zhao Y, Zhang L, Wang H, Song J, Hou X. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey. *J Gastroenterol Hepatol* 2017; **32**: 1018-1025 [PMID: [27862281](#) DOI: [10.1111/jgh.13642](#)]
- 10 **Wang B**, Zhao W, Zhao C, Jin H, Zhang L, Chen Q, Wang B. What impact do Rome IV criteria have on patients with IBS in China? *Scand J Gastroenterol* 2019; **54**: 1433-1440 [PMID: [31829752](#) DOI: [10.1080/00365521.2019.1698650](#)]
- 11 **Sach J**, Bolus R, Fitzgerald L, Naliboff BD, Chang L, Mayer EA. Is there a difference between abdominal pain and discomfort in moderate to severe IBS patients? *Am J Gastroenterol* 2002; **97**: 3131-3138 [PMID: [12492200](#) DOI: [10.1111/j.1572-0241.2002.07110.x](#)]
- 12 **Lembo T**, Naliboff B, Munakata J, Fullerton S, Saba L, Tung S, Schmulson M, Mayer EA. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. *Am J Gastroenterol* 1999; **94**: 1320-1326 [PMID: [10235213](#) DOI: [10.1111/j.1572-0241.1999.01009.x](#)]
- 13 **Pan G**, Lu S, Ke M, Han S, Guo H, Fang X. Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling. *Chin Med J (Engl)* 2000; **113**: 35-39 [PMID: [11775207](#)]
- 14 **Zhu L**, Huang D, Shi L, Liang L, Xu T, Chang M, Chen W, Wu D, Zhang F, Fang X. Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrhea. *Health Qual Life Outcomes* 2015; **13**: 49 [PMID: [25925746](#) DOI: [10.1186/s12955-015-0243-3](#)]
- 15 **Vakil N**, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006; **101**: 1900-20; quiz 1943 [PMID: [16928254](#) DOI: [10.1111/j.1572-0241.2006.00630.x](#)]
- 16 **Huang WW**, Zhou FS, Bushnell DM, Diakite C, Yang XH. Cultural adaptation and application of the IBS-QOL in China: a disease-specific quality-of-life questionnaire. *Qual Life Res* 2007; **16**: 991-996 [PMID: [17440830](#) DOI: [10.1007/s11136-006-9141-9](#)]
- 17 **Patrick DL**, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. *Dig Dis Sci* 1998; **43**: 400-411 [PMID: [9512138](#) DOI: [10.1023/a:1018831127942](#)]
- 18 **Hamilton M**. The assessment of anxiety states by rating. *Br J Med Psychol* 1959; **32**: 50-55 [PMID: [13638508](#) DOI: [10.1111/j.2044-8341.1959.tb00467.x](#)]
- 19 **Hamilton M**. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; **23**: 56-62 [PMID: [14399272](#) DOI: [10.1136/jnnp.23.1.56](#)]
- 20 **Black CJ**, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. *Clin Gastroenterol Hepatol* 2020; **18**: 392-398.e2 [PMID: [31154027](#) DOI: [10.1016/j.cgh.2019.05.037](#)]
- 21 **Vork L**, Weerts ZZRM, Mujagic Z, Kruimel JW, Hesselink MAM, Muris JWM, Keszthelyi D, Jonkers DMAE, Masclee AAM. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study. *Neurogastroenterol Motil* 2018; **30** [PMID: [28804974](#) DOI: [10.1111/nmo.13189](#)]
- 22 **Kanazawa M**, Miwa H, Nakagawa A, Kosako M, Akiho H, Fukudo S. Abdominal bloating is the most bothersome symptom in irritable bowel syndrome with constipation (IBS-C): a large population-based Internet survey in Japan. *Biopsychosoc Med* 2016; **10**: 19 [PMID: [27274765](#) DOI: [10.1186/s13030-016-0070-8](#)]
- 23 **Hertig VL**, Cain KC, Jarrett ME, Burr RL, Heitkemper MM. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. *Nurs Res* 2007; **56**: 399-406 [PMID: [18004186](#) DOI: [10.1097/01.NNR.0000299855.60053.88](#)]
- 24 **Ludidi S**, Mujagic Z, Jonkers D, Keszthelyi D, Hesselink M, Kruimel J, Conchillo J, Masclee A. Markers for visceral hypersensitivity in patients with irritable bowel syndrome. *Neurogastroenterol Motil* 2014; **26**: 1104-1111 [PMID: [24404974](#) DOI: [10.1111/nmo.12440](#)]

- 24920528 DOI: [10.1111/nmo.12365](https://doi.org/10.1111/nmo.12365)]
- 25 **Josefsson A**, Rosendahl A, Jerlstad P, Näslin G, Törnblom H, Simrén M. Visceral sensitivity remains stable over time in patients with irritable bowel syndrome, but with individual fluctuations. *Neurogastroenterol Motil* 2019; **31**: e13603 [PMID: [31012215](https://pubmed.ncbi.nlm.nih.gov/31012215/) DOI: [10.1111/nmo.13603](https://doi.org/10.1111/nmo.13603)]
- 26 **Wouters MM**, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar YA, Valdez-Morales EE, Nasser Y, Van Veldhoven PP, Vanbrabant W, Van der Merwe S, Mols R, Ghesquière B, Cirillo C, Kortekaas I, Carmeliet P, Peetermans WE, Vermeire S, Rutgeerts P, Augustijns P, Hellings PW, Belmans A, Vanner S, Bulmer DC, Talavera K, Vanden Berghe P, Liston A, Boeckxstaens GE. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. *Gastroenterology* 2016; **150**: 875-87.e9 [PMID: [26752109](https://pubmed.ncbi.nlm.nih.gov/26752109/) DOI: [10.1053/j.gastro.2015.12.034](https://doi.org/10.1053/j.gastro.2015.12.034)]
- 27 **Larsson MB**, Tillisch K, Craig AD, Engström M, Labus J, Naliboff B, Lundberg P, Ström M, Mayer EA, Walter SA. Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. *Gastroenterology* 2012; **142**: 463-472.e3 [PMID: [22108191](https://pubmed.ncbi.nlm.nih.gov/22108191/) DOI: [10.1053/j.gastro.2011.11.022](https://doi.org/10.1053/j.gastro.2011.11.022)]
- 28 **Lee KN**, Lee OY, Choi MG, Sohn CI, Huh KC, Park KS, Kwon JG, Kim N, Rhee PL, Myung SJ, Lee JS, Lee KJ, Park H, Lee YC, Choi SC, Jung HK, Jee SR, Choi CH, Kim GH, Park MI, Sung IK. Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium. *J Neurogastroenterol Motil* 2014; **20**: 113-121 [PMID: [24466452](https://pubmed.ncbi.nlm.nih.gov/24466452/) DOI: [10.5056/jnm.2014.20.1.113](https://doi.org/10.5056/jnm.2014.20.1.113)]
- 29 **Johnston JM**, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ. Linaclotide improves abdominal pain and bowel habits in a phase IIB study of patients with irritable bowel syndrome with constipation. *Gastroenterology* 2010; **139**: 1877-1886.e2 [PMID: [20801122](https://pubmed.ncbi.nlm.nih.gov/20801122/) DOI: [10.1053/j.gastro.2010.08.041](https://doi.org/10.1053/j.gastro.2010.08.041)]
- 30 **Urgesi R**, Casale C, Pistelli R, Rapaccini GL, de Vitis I. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome. *Eur Rev Med Pharmacol Sci* 2014; **18**: 1344-1353 [PMID: [24867512](https://pubmed.ncbi.nlm.nih.gov/24867512/)]
- 31 **Yao X**, Yang YS, Cui LH, Zhao KB, Zhang ZH, Peng LH, Guo X, Sun G, Shang J, Wang WF, Feng J, Huang Q. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. *J Gastroenterol Hepatol* 2012; **27**: 760-765 [PMID: [21929652](https://pubmed.ncbi.nlm.nih.gov/21929652/) DOI: [10.1111/j.1440-1746.2011.06930.x](https://doi.org/10.1111/j.1440-1746.2011.06930.x)]
- 32 **Zhao Y**, Zou D, Wang R, Ma X, Yan X, Man X, Gao L, Fang J, Yan H, Kang X, Yin P, Hao Y, Li Q, Dent J, Sung J, Halling K, Wernersson B, Johansson S, He J. Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact. *Aliment Pharmacol Ther* 2010; **32**: 562-572 [PMID: [20497141](https://pubmed.ncbi.nlm.nih.gov/20497141/) DOI: [10.1111/j.1365-2036.2010.04376.x](https://doi.org/10.1111/j.1365-2036.2010.04376.x)]
- 33 **Fan WJ**, Xu D, Chang M, Zhu LM, Fei GJ, Li XQ, Fang XC. Predictors of healthcare-seeking behavior among Chinese patients with irritable bowel syndrome. *World J Gastroenterol* 2017; **23**: 7635-7643 [PMID: [29204063](https://pubmed.ncbi.nlm.nih.gov/29204063/) DOI: [10.3748/wjg.v23.i42.7635](https://doi.org/10.3748/wjg.v23.i42.7635)]
- 34 **Xiong LS**, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. *Aliment Pharmacol Ther* 2004; **19**: 1217-1224 [PMID: [15153175](https://pubmed.ncbi.nlm.nih.gov/15153175/) DOI: [10.1111/j.1365-2036.2004.01939.x](https://doi.org/10.1111/j.1365-2036.2004.01939.x)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

